Epic Bio is a pioneering startup operating in the field of genetic medicine, with a focus on developing innovative therapies to control gene expression and treat complex diseases. The company leverages the power of epigenetics, a system present in all mammalian cells that controls gene expression, to create new therapeutic possibilities.

The company's primary offering is its Gene Expression Modulation System (GEMS), a platform that allows for the creation of customized therapies for specific disease indications. This "mix and match" platform uses a toolbox of epigenomic modulators, providing vast possibilities for disease treatment.

Epic Bio operates in the biotechnology market, serving clients in the healthcare sector, including hospitals, clinics, and other medical institutions. The company's business model revolves around the development and sale of its GEMS platform and the therapies it can create. Revenue is generated through the sale of these therapies to healthcare providers and institutions.

The company also prides itself on being a place where individuals can advance their careers, do groundbreaking work, and make a real impact on the world. This is evidenced by their recognition in the 2023 Endpoints 20 Under 40 and the 2022 Endpoints Women in R&D.

Keywords: Genetic Medicine, Epigenetics, Gene Expression, Therapies, Disease Treatment, Biotechnology, Healthcare, GEMS Platform, Career Advancement, Recognition.